Stockreport

Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%

Aerie Pharmaceuticals, Inc.  (AERI) 
Last aerie pharmaceuticals, inc. earnings: 2/20 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.aeriepharma.com/investor-relations
PDF - Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - DURHAM, N.C.--(BUSINESS WIRE)-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an op [Read more]